Pictured: Jedd Wolchok, Alexandra Snyder Charen and Timothy Chan
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, November 20, 2014

In people with melanoma who respond to the drug ipilimumab, certain mutations make tumors more visible to the immune system.

Michel Sadelain and Prasad Adusumilli
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, November 19, 2014

A study in mouse models suggests how modified T cells may be used to treat tumors in the area just outside the lungs.

Pictured: Experimental Brain Tumor
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, September 18, 2014

Researchers have engineered a gene into therapeutic cells that allows them to turn off tumor growth if some of the cells become cancerous.

Pictured: Jedd Wolchok
MSK at ASCO
By Media Staff  |  Wednesday, June 4, 2014

Our experts offer their perspective in major media outlets on recent research into drug- and cell-based immunotherapies for cancer.

Pictured: Helen McArthur
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, June 3, 2014

The treatment combines a technique called cryoablation, or freezing of the tumor, with an immunotherapy drug.

pictured: Martin S. Tallman
Profile
By Maureen Salamon, BA, Freelance Writer  |  Monday, May 19, 2014

Leukemia Specialist Martin Tallman discusses how research has led to improvements in the treatment of leukemia and what challenges remain.

Pictured: Jedd Wolchok
In the News
By Jim Stallard, MA, Writer/Editor  |  Friday, May 2, 2014

Memorial Sloan Kettering physician-scientist Jedd Wolchok describes striking advances in cancer immunotherapy in New York Times and Scientific American.

Pictured: José Baselga
Announcement
By Media Staff  |  Thursday, April 10, 2014

Discoveries made at Memorial Sloan Kettering receive recognition at the 2014 Annual Meeting of the American Association for Cancer Research.

Pictured: Low-dose CT scans
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, December 26, 2013

The American Society of Clinical Oncology’s annual report on top clinical cancer advances of the year once again features several studies led by Memorial Sloan Kettering researchers.

Pictured: T cells
In the News
By Julie Grisham, MS, Science Writer/Editor  |  Monday, December 23, 2013

Memorial Sloan Kettering researchers have played a major role in cancer immunotherapy research, named “Breakthrough of the Year” by Science magazine.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the News
By Christina Pernambuco-Holsten, MA  |  Friday, December 6, 2013

Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.

Pictured: Jedd Wolchok & Richard Carvajal
In the Clinic
By Media Staff  |  Monday, June 3, 2013

Two Memorial Sloan Kettering studies that hold promise for the treatment of advanced uveal (eye) melanoma and advanced skin melanoma are making headlines at the 49th Annual Meeting of the American Society of Clinical Oncology.

Pictured: Jedd Wolchok
In the Clinic
By Media Staff  |  Thursday, April 4, 2013

Early research led by investigators at Memorial Sloan Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Pictured: Prasad Adusumilli
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, January 3, 2013

A team from Memorial Sloan Kettering has found that the makeup of immune cells in a lung tumor and in tissue surrounding a tumor can predict whether the cancer will recur after surgery.

Pictured: Michel Sadelain
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, December 18, 2012

Memorial Sloan Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.

Center News

Stay Informed

Get the latest information about cancer care and research every month.